Integral Diagnostics
- Short interest
- 1.91%
- −0.40 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 7.1M
- Shares on issue
- 373.697M
Integral Diagnostics (IDX) Short Interest
Integral Diagnostics (ASX:IDX) had 1.91% of shares reported as short positions as of 8 Oct 2026, representing 7,146,778 shares. Integral Diagnostics operates in the Health Care Equipment & Services industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Integral Diagnostics
Integral Diagnostics is a leading provider of medical imaging services in Australia and New Zealand, offering a comprehensive range of diagnostic imaging services. The company is known for its advanced technology and skilled radiologists, ensuring high-quality patient care and accurate diagnostics.
Company profile →Integral Diagnostics (ASX:IDX) has 1.91% of its shares on issue reported as short positions as of 8 Oct 2026, or about 7,146,778 shares. Over the past 30 days that figure has fallen 0.40 percentage points, and over 90 days it has risen 0.51 percentage points. Its highest recorded short interest was 5.56% in October 2024. IDX is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads IDX today
- Zanger BreakoutWatchScore 55rank 26 of 1942
- CAN SLIMWatchScore 39rank 151 of 1541
- Minervini Trend TemplateWatchScore 17rank 1026 of 1716
- Crowded-Short BreakoutWatchScore 28rank 159 of 1502
- Quality compoundersWatchScore 42rank 209 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
IDX fundamentals
In the year to 30 Jun 2026, Integral Diagnostics (ASX:IDX) recorded revenue of A$788.6M and net profit after tax of A$21.9M. A year earlier it recorded revenue of A$627.2M and net profit after tax of A$4.7M. Year-on-year growth: revenue +25.7% (FY), EPS +262.5% (TTM). Net margin 2.8%, return on equity 3.2% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest IDX news
All news- Change of Director's Interest Notice - Toby Hall Chair
asx · 5 Oct 2026
- Application for quotation of securities - IDX
asx · 1 Oct 2026
- Notification regarding unquoted securities - IDX
asx · 1 Oct 2026
Company details
website
address
More Health Care Equipment & Services Stocks
Other shorted stocks in this sector
Be the first to discuss IDX
Start a research thread or post the first pulse update